DIA
BVS icon

Dean Investment Associates’s Bioventus BVS Stock Holding History

Dean Investment Associates’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-62,573
Closed -$882K – 226
2022
Q1 		$882K Sell
62,573
-8,561
-12% -$115K 0.16% 192
2021
Q4 		$1.03M Buy
71,134
+6,907
+11% +$98.2K 0.18% 194
2021
Q3 		$909K Buy
+64,227
New +$988K 0.17% 197

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Dean Investment Associates's BVS Position: Q2 2022 in Review

Dean Investment Associates sold out of Bioventus (BVS) in Q2 2022, closing a stake of 62,573 shares — an estimated $882K sold.

Dean Investment Associates first reported a position in BVS in Q3 2021 and held it in 3 quarters. The position peaked at $1.03M in Q4 2021. 98 funds tracked by Wall St. Rank hold BVS as of Q2 2022.

  • Dean Investment Associates reported no remaining Bioventus position as of Q2 2022 after selling out during the quarter.
  • Dean Investment Associates sold 62,573 Bioventus shares in Q2 2022, an estimated $882K.
  • Dean Investment Associates first reported a position in Bioventus in Q3 2021 and held it in 3 quarters.
  • Dean Investment Associates's Bioventus position peaked at $1.03M in Q4 2021.
  • 98 funds tracked by Wall St. Rank held Bioventus as of Q2 2022.

Based on Dean Investment Associates's 13F filing for Q2 2022, filed 18 Aug 2022.